An overview of VH-COMSAVAC

5 April 2023

Camila Picchio, MPH
Barcelona Institute for Global Health (ISGlobal)
Camila.picchio@isglobal.org
Background

Eliminate viral hepatitis as a public health problem by 2030
Reduction in incidence by 90% and mortality by 65%

Tackle the entire disease pathway and reduce cancers caused by infections (HBV, HCV, HPV)
Background

Targeted screening of migrants from countries of intermediate or high endemicity is recommended.
Project Objective

Scale-up and adapt community-based viral hepatitis (HBV and HCV) testing and HBV vaccination models of care among marginalised populations with documented high HBV and HCV incidence and prevalence using simplified diagnostic tools and patient-centred referral processes to reduce liver cancer-associated mortality.

- 1€ million total budget
- Co-funded by the EU HaDEA program
- 24 month duration
- 4 project partners in Italy, Greece, and Spain
Advisory Board and Associated Partners

**Advisory Board**
- Hepatitis B and C Public Policy Association
- ICE-HBV
- EASL
- World Health Organization
- ECDC
- Viral Hepatitis Prevention Board
- International Liver Cancer Movement
- ESCMID

**Associated Partners**
- ELPA
- European Liver Patients' Association
- EUPHA
- World Federation of Public Health Associations
- Generalitat de Catalunya
- Departament de Salut
Implementation in Spain by ISGlobal

1. First documented visit with a liver specialist
2. Post-test counselling
3. HBV vaccination
ISGlobal results, 2020-2022

- 650 people screened
- 42 yrs (SD =10)
- 23% recently arrived
- 72% from Ghana
- 10.5% HBsAg+

HCV added in June 2022
Data management

**REDCap - Research Electronic Data Capture:**
Browser-based software used to design clinical and translational research databases.

*Data can be introduced and accessed* in REDCap using a computer through the browser access, or using tablets which include the REDCap App.
WP 5: Economic Evaluation & Value-Based Assessment

**Value-based assessment tool**

Development of a **value-based assessment tool**, which includes the indicators in the following dimensions:
- Clinical Outcomes (epidemiological indicators);
- Patient Reported Clinical Outcomes;
- Patient Reported Experience of Care;
- Per-capita cost;
- Physicians’ burnout.

**Economic Evaluation**

Economic evaluation to assess cost-effectiveness and value brought to patients with HBV through community-based care.
Thank you for your attention!